Melanoma Posts on Medivizor
Navigation Menu

Melanoma Posts on Medivizor

Evaluating long-term outcomes of nivolumab plus ipilimumab for patients with advanced melanoma

Posted by on Oct 20, 2019 in Melanoma | 0 comments

In a nutshell This study compared nivolumab (Opdivo) plus ipilimumab (Yervoy) to either drug alone for the treatment of advanced melanoma. The authors concluded that nivolumab plus ipilimumab or nivolumab alone increased survival compared to ipilimumab alone for these patients. Some background Advanced melanoma is a type of skin cancer that...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Melanoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Looking for patients with advanced melanoma to test a combination of antibody and enzyme drugs

Posted by on Aug 31, 2019 in Melanoma | 0 comments

In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...

Read More

Looking for participants with metastatic melanoma to test a new immunotherapy

Posted by on Aug 14, 2019 in Melanoma | 0 comments

In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...

Read More